Full Length Research Paper
References
Bannerman TL (2003). Staphylococcus, Micococcus and other Catalase – positive cocci that grow aerobically. In P.R. Murray, E.J. Bron, J.H. Jorgensen, M.A. Pfaller, R.H. Yolken (edition) Manual of clinical microbiology 8th edition. ASM Press, Washington D.C. Center for Disease Control (2007). Guidelines for Infection Control in Healthcare Personnel. Centers Dis. control Prevention 12:30-36. | ||||
Centers for Disease Control and Prevention CDC (2010). Laboratory detection of oxxacillin/methicillin-resistant Staphylococcus aureus. National Center for Emerging and Zoonotic Infectious Disese. | ||||
Chambers HF (1997). Methicillin-Resistance in Staphylococci; Molecular an Biochemical Basis and clinical implications. Clin. Microbiol. Rev. 10:781-791 Pubmed |
||||
Chambers HF (2001). The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. 7:17-82. Crossref |
||||
Chigbu CO, Ezereonye OU (2003). Antibiotic resistant Staphylococcus aureus in Abia state of Nigeria. Afr. J. Biotechnol. 2:374-378. | ||||
Clinical, and Laboratory Standard Institute, (2007). Performance Standard for antimicrobial susceptibility testing. CLSI approved standard M100-517. Clinical and Laboratory Standards Institute. Wayne. | ||||
Deurenberg RH, Vink C, Kalenic S, Friedrich AW, Bruggeman CA, Stobberingh EE (2007). The molecular evolution of Methicillin–resistant Staphylococas aureus Clin. Microbial Infect. 13:222-235. |
||||
Klein E, Smith DL, Laxminarayan R (2007). Hospitalization and Deaths caused by Methicilin–Resistant Staphylococcus aureus. United States 1999–2005. Emerg. Infect. Dis. 13:1840–1846. Crossref |
||||
Kluytmans J, Van Belkum A, Verbrugh H (1997). Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin. Microbial Rev. 10:505–520. Pubmed |
||||
Klevens (2007). Invasive Methicillin–Resistant Staphylococcus areus Infections in the United States. JAMA 201:360-372. | ||||
Noskin GA, Rusin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Smulders M, Lapetina E, Gemmene (2005). The boding of Staphylococcus aureus infection on Hospitals in the United States: Analysis of the 2000 and 2001 Nationwide inpatient sample Data base. Ach. Int. Med. 165:1756–1761. Crossref |
||||
Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Jacobson C, Smulders M, Gemmen E, Bharmal M (2007). National trends I Staphylococcus are aureus infection rates: impact on economic binder and mortality over a 6–years period. Clin. Infect. Dis. 45(9):1132-40. |
||||
Proctor RA (2008). Role of folate antagonists in the treatment of methicillin resistant Staphylococcus aureus Infection Clin. Infect. Dis. 46:584–593. Crossref |
||||
Reuters (2009). "Study: Beachgoers More Likely to Catch MRSA". FoxNews.com. | ||||
Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Mioduddin A (1999). The Economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg. Infect. Dis. 5:9–17. Crossref |
||||
Smith TL, Pearson ML, Wikox KR (1999). For the Glycopeptide –intermediate Staphylococcus aureus N. Engl. J. Med. 340:493-501. Crossref |
||||
Stein R (2007). Drug-resistant staph. germ's toll is higher than thought. Washington Post. 41:74-77. | ||||
Taiwo SS, Onile BA, Akanbi AA (2004). Methicillin-resistant Staphylococcus aureus (MRSA) isolates in Ilorin, Nigeria. Afr. J. Exp. Microbiol. 5:189-199. |
||||
Uaboi-Egbenni PO (2003). Incidence of Staphylococcus aureus among healthy humans in Lagos and its Environs. Nigeria J. Microbiol. 17:162-172. |
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0